Cardiovascular Systems Inc (CSII) was Reiterated by Needham to “Buy” according to the research note released today. The brokerage firm has raised the Price Target to $ 23 from a previous price target of $20 . Needham advised their investors in a research report released on Jun 29, 2016.
Many Wall Street Analysts have commented on Cardiovascular Systems Inc. Company shares were Reiterated by Needham on May 5, 2016 to “Buy”, Firm has raised the Price Target to $ 20 from a previous price target of $16 .Needham Upgraded Cardiovascular Systems Inc on Apr 1, 2016 to ” Buy”, Price Target of the shares are set at $16.
On the company’s financial health, Cardiovascular Systems Inc reported $-0.31 EPS for the quarter, beating the analyst consensus estimate by $ 0.13 according to the earnings call on May 4, 2016. Analyst had a consensus of $-0.44. The company had revenue of $44.50 million for the quarter, compared to analysts expectations of $42.55 million. The company’s revenue was down -5.3 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $-0.34 EPS.
Cardiovascular Systems Inc closed down -0.825 points or -4.69% at $16.775 with 2,57,512 shares getting traded on Monday. Post opening the session at $17.48, the shares hit an intraday low of $16.57 and an intraday high of $17.55 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.
In a different news, on Jun 1, 2016, Leslie Trigg (director) sold 3,500 shares at $33.86 per share price. According to the SEC, on Jan 25, 2016, Scott R. Ward (CEO) purchased 2,700 shares at $9.30 per share price. On Oct 6, 2015, Robert J. Thatcher (Chief Healthcare Policy Off’r) sold 64,700 shares at $16.31 per share price, according to the Form-4 filing with the securities and exchange commission.
Cardiovascular Systems Inc. is a medical technology company. The Company is engaged in treating patients suffering from peripheral and coronary arterial diseases. It has developed an orbital atherectomy technology for peripheral and coronary commercial applications. Its peripheral arterial disease systems are catheter-based platforms that treat plaque types in leg arteries both above and below the knee. Its products include Stealth 360 degree Peripheral Orbital Atherectomy System (OAS); the Diamondback 360 Peripheral OAS (Diamondback 360 Peripheral) and Diamondback 360 Peripheral Diamondback 360 60cm Peripheral OAS and Diamondback 360 4 French 1.25 Peripheral (collectively called as peripheral arterial disease systems (PAD systems)). Its coronary product the Diamondback 360 Coronary OAS (CAD System) is a catheter-based platform designed to facilitate stent delivery in patients with coronary arterial disease (CAD). The CAD System design is customized for the coronary application.